Form 4: Hims & Hers CLO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,637 shares of Class A Common Stock for $42.53 per share under a pre-arranged trading plan.

Summary

• Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A Common Stock.
• The transaction involved the disposition of 2,637 shares.
• The shares were sold at a price of $42.53 per share.
• The total value of the shares sold was approximately $112,164.61.
• Following this transaction, Soleil Boughton beneficially owns 155,856 shares of Class A Common Stock.
• The sale was executed on November 10, 2025.
• This transaction was made pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on August 28, 2024.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of an insider stock sale executed under a pre-arranged trading plan, which is a common practice and does not inherently indicate positive or negative company performance or a change in management's outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive positioning for Hims & Hers Health, Inc. It reflects an individual executive's pre-planned share disposition.

Stakeholder Impact

• Shareholders might note the insider sale, but given it was executed under a Rule 10b5-1 plan, it is generally considered a pre-planned, non-discretionary event rather than a signal of immediate concern regarding company performance.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a Rule 10b5-1 trading plan. Such pre-scheduled transactions are common and generally do not reflect a change in management's outlook on the company's fundamentals. The volume of shares sold (2,637) is a small fraction of the total shares beneficially owned (155,856), further suggesting it's a planned liquidity event rather than a bearish signal. Therefore, it does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Hims & Hers Health, HIMS, Soleil Boughton, Chief Legal Officer, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, Class A Common Stock